BioSpace News Archive

Business

Seattle Children’s Opens New Clinic to Better Serve Families in North King, Snohomish, Whatcom and Skagit Counties

The new clinic will provide access to more than 18 pediatric specialty care services in the North Sound region

August 15, 2018
·
5 min read
Pharm Country

SoundPrint Finds Most NYC Restaurants and Bars Potentially Endanger Patrons’ Hearing Health

Groundbreaking Study Raises Awareness of Increasing Noise Pollution, Finding Majority of NYC Restaurants & Bars Too Loud for Conversation

August 15, 2018
·
4 min read
Business

Jim Worthington to Deliver Opening Keynote at the 5th Annual Motionsoft Technology Summit

Motionsoft announced that Jim Worthington will deliver the opening keynoted for the 5th annual Motionsoft Technology Summit in Washington, D.C.

August 15, 2018
·
4 min read
Genetown

Branded Direct-to-Consumer Advertising Likely to Provide a Bump in Patient Requests for Sanofi/Regeneron’s Dupixent, but Insurance Coverage and Out-of-Pocket Costs Continue to be Key Barriers for the Only Approved Atopic Dermatitis Biologic

According to the latest update from Spherix Global Insights, while dermatologists continue to report high satisfaction with the first FDA approved biologic, there is still a large unmet need for new pharmacologic treatments for atopic dermatitis.

August 15, 2018
·
4 min read
BioMidwest

Sysmex Introduces New Standard In Diagnostic Device Training With Opening Of Center For Learning

98,000-square-foot training facility triples training capacity and offers seven fully equipped studios for livestreamed courses across U.S. and Canada via internet

August 15, 2018
·
6 min read
BioMidwest

KANSAS CITY SITS AT EPICENTER OF GLOBAL ANIMAL HEALTH’S FUTURE

Kansas City is the bustling center of the global animal health industry and regarded as the world’s best place to advance new technologies and solutions to solve global issues.

August 15, 2018
·
3 min read
Drug Development

Ultragenyx Announces First Patient Dosed in Phase 1/2 study of DTX401, a Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa); FDA Grants Fast Track Designation to Gene Therapy Program

Ultragenyx Pharmaceutical Inc.(NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that the first patient has been dosed in the Phase 1/2 study of DTX401, an adeno-associated virus vector based gene therapy for the treatment of patients with glycogen storage disease type Ia (GSDIa).

August 15, 2018
·
5 min read
Biotech Bay

Ultragenyx Announces Positive CHMP Opinion for Mepsevii™ (vestronidase alfa) For the Treatment of Mucopolysaccharidosis VII

ltragenyx Pharmaceutical Inc.(NASDAQ:RARE) today announced that the Committee for Medicinal Products for Human Use(CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion recommending the marketing authorization under exceptional circumstances of Mepsevii™ (vestronidase alfa) for the treatment of non-neurological manifestations of Mucopolysaccharidosis VII (MPS VII; Sly syndrome).

August 15, 2018
·
6 min read
Biotech Bay

Ultragenyx to Present at Upcoming Investor Conferences .

Ultragenyx Pharmaceutical Inc.(NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, will present at the following investor conferences.

August 15, 2018
·
1 min read
Drug Development

Ultragenyx and Kyowa Kirin Announce Publication of Phase 2 Study Results Demonstrating that Crysvita® (burosumab) Improved Outcomes in Children with X-linked Hypophosphatemia in the New England Journal of Medicine

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Kyowa Hakko Kirin Co. Ltd, and Kyowa Kirin International PLC today announced that the results of a pediatric Phase 2 clinical trial of Crysvita® (burosumab) for the treatment of X-linked hypophosphatemia (XLH) in children aged 5 to 12 years were published online by the New England Journal of Medicine (NEJM).

August 15, 2018
·
10 min read